Diffuse large B cell lymphoma (DLBCL) is the commonest form of non-Hodgkin lymphoma and is incurable in roughly 30% of cases. Here, we demonstrate addiction of both major subtypes of DLBCL to the expression of the transcription factor OCT2 and its co-activator OCA-B. We clarify the role of OCT2 in normal germinal center biology and identify the genes and pathways that it regulates in malignant B cells. Our findings suggest that pharmacological agents designed to target OCT2 itself or the OCT2-OCA-B interface would be an effective and non-toxic therapeutic strategy in DLBCL.
\body OCT2, encoded by the gene POU2F2, is a B cell-restricted transcription factor that binds to an octamer DNA motif 5'-ATGCAAAT-3' in the promoters of immunoglobulin genes (1) . It belongs to the POU domain family of transcription factors that uses both a POU homeodomain and a POU-specific domain to bind DNA (2) (3) (4) . DNA binding induces a conformational change in the POU domain that permits recruitment of the coactivator OCA-B (also known as BOB-1 or OBF1, encoded by POU2AF1), which stabilizes the complex and further enhances transcriptional activation (5) (6) (7) (8) (9) (10) .
OCT2 and OCA-B are largely restricted in expression to the B cell lineage (1, (7) (8) (9) (10) . Although OCT2 was initially thought to direct the B cell-restricted expression of immunoglobulin genes by binding to octamer motifs in their promoters, OCT2 knockout cell lines were subsequently shown to transcribe immunoglobulin genes normally (11) . Since mice with germline deletion of Pou2f2 die shortly after birth from an undetermined cause (12) , fetal liver and bone marrow chimeras have been used to investigate the function of OCT2-deficient B cells. Such mice have reduced B1 and marginal zone B cells as well as reduced B cell proliferation and immunoglobulin secretion when stimulated in vitro (12, 13) . The role of OCT2 in antigen-dependent germinal center responses is controversial, with one study finding a defect in the germinal center response to NP-OVA immunization (14) and another reporting normal germinal center formation after influenza challenge (15). OCA-B deficient mice have normal B cell development but are unable to mount a germinal center response (16-18). Thus, current evidence suggests important functions for OCT2 and OCA-B in the later stages of B cell differentiation, but the precise role, if any, for OCT2 in the germinal center reaction is unclear.
Germinal centers form when a mature B cell encounters antigen in the context of CD4 T cell help, and are characterized by intense B cell proliferation and hypermutation of immunoglobulin genes (19). B cells with improved affinity for the immunizing antigen as a result of immunoglobulin hypermutation are selected and eventually differentiate into either memory B cells or long-lived plasma cells. Diffuse large B cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, is derived from B cells that have transited the germinal center (19). The germinal center B cell-like (GCB) subtype of DLBCL retains expression of germinal center B cell-restricted genes whereas the activated B cell-like (ABC) DLBCL subtype appears to be derived from postgerminal center, plasmablastic cells (20) . Both OCT2 and OCA-B are highly expressed in normal germinal center B cells and in almost all cases of DLBCL (21, 22). A role for OCA-B in DLBCL was proposed based on the identification of a DLBCL-specific superenhancer near the OCA-B promoter, but this study did not investigate whether OCA-B acts by binding to OCT2 or to the related and ubiquitously expressed POU domain factor OCT1 (23). One study of follicular lymphoma described apparent loss-of-function mutations in POU2F2, leading to the suggestion that OCT2 may prevent the formation of lymphomas (24). In the present study, we set out to clarify the role of OCT2 in normal germinal center reactions and to determine whether OCT2 acts to promote or restrain the development of germinal center-derived lymphomas.
Results
Abnormal germinal center function and plasma cell differentiation in OCT2-deficient mice. We generated conditional Pou2f2 knockout mice from targeted embryonic stem cells created by the European Mouse Knockout Consortium. Lox P sites placed on either side of exons 8-11 ensured deletion of the entire POU domain (Fig.  S1A) . Pou2f2 fl/fl mice were crossed first to FLPE recombinase mice (25) to excise the neomycin cassette, and then to ERT2-Cre mice in which the Cre recombinase is tamoxifen-inducible (26). We confirmed correct gene targeting by Southern blotting (Fig. S1B-D) and observed efficient Cre-mediated deletion in germinal center B cells and in splenic B cells (Fig. S1E,F) . Cre-mediated deletion was associated with persistence of a Pou2f2 transcript and the production of an unstable protein that lacked exons 8-11 (Fig.  S1F,G) . Homozygous deletion of Pou2f2 was not associated with any sign of ill health or altered behavior in mice observed for more than two months after deletion. Heterozygous floxed (Pou2f2 fl/wt ), Cre-expressing mice were used as controls. Seven days after immunization with sheep red blood cells, the numbers of splenic B cells, T cells and germinal center B cells were normal, with no difference in the proportion of germinal center light zone (centrocyte) and dark zone (centroblast) cells (Fig. 1A & Fig. S2A,B) . Similarly, when immunized with the thymus-dependent immunogen NP-KLH, knockout mice had normal numbers of germinal center B cells (Fig. S2B) . However, the function of the germinal center B cells in knockout animals was not normal in that their cell cycle progression was reduced at 14 days after immunization with NP-KLH, as assessed by incorporation of 5-ethynyl-2'-deoxyuridine (EDU) (Fig. 1B & Fig. S2C ). Furthermore, serum antigen-specific immunoglobulin levels were reduced in knockout animals after immunization with NP-KLH (Fig. 1C) . By day 28, NP-specific IgM, total NP-specific IgG1 and high affinity NP-specific IgG1 levels were reduced by 5.5-, 10.6-and 61-fold, respectively. Moreover, NP-specific antibody-secreting cells were almost absent in both spleen and bone marrow when measured by ELISpot assays 28 days after immunization (Fig. 1D & Fig. S2D ). In contrast, normal numbers of memory B cells (Gr1 -, CD11d -, IgM -, IgD -, CD138 -, NP + , IgG1 + , CD38 + ) were present 28 days after immunization (Fig. S2E ), and were able to expand normally when mice were rechallenged with NP-KLH 30 days after primary immunization (Fig. 1E & Fig. S2F ). However, OCT2-deficient mice were unable to produce immunoglobulin in response to secondary immunization (Fig. S2G) . Thus, while OCT2-deficient mice were able to initiate germinal center formation normally and produce normal numbers of memory B cells, the proliferation of B cells within the germinal center was reduced and the production of antibody-secreting plasma cells was blocked.
DLBCL cell lines are addicted to expression of both OCT2 and OCA-B. Because of the germinal center phenotype in Pou2F2 knockout mice, we examined the dependence of human lymphoma cell lines on OCT2 by RNA interference. Small hairpin RNA (shRNA)-mediated knockdown of OCT2 expression was toxic for most DLBCL cell lines tested, but not for T cell, Hodgkin, or mantle cell lymphoma lines (Fig. S3A) . In a larger panel of cell lines, knockdown of OCT2 was confirmed to be essential in both the ABC and GCB DLBCL lines, but not in control T cell lines ( Fig. 2A) . A similar spectrum of toxicity was observed using a second, independent OCT2 shRNA ( Fig. S3B) , and the toxicity of both shRNAs could be reversed by ectopic expression of OCT2 (Fig. S3C) . OCT2-depleted cells showed both increased apoptotic cell death, as measured by cleavage of caspase 3 and PARP, and reduced cell cycle progression, with an increase in G1 phase cells (Fig. S3D,E) . Similarly, knockdown of OCA-B was toxic for all ABC and GCB DLBCL cell lines tested, but not T cell lines (Fig. 2B) , demonstrating the essential role of OCT2 and OCA-B in both common subtypes of DLBCL.
OCT2 and OCA-B bind an overlapping repertoire of genes. To identify gene targets of OCT2 and OCA-B, we performed genome-wide chromatin immunoprecipitation analysis (ChIP-Seq) in the HBL1 ABC DLBCL line. Both OCT2 and OCA-B bound a large number of genomic sites, with 29,208 and 28,376 binding peaks, respectively. These were enriched in promoter-proximal regions: 38% of OCT2 peaks and 34% of OCA-B peaks were located within a window from 15 kb upstream to 2 kb downstream of a transcriptional start site (TSS) (Fig. 3A) . Analysis of promoter peaks revealed OCT2 and OCA-B interaction with an overlapping repertoire of protein-coding genes (Fig. 3B) . OCT2 peaks frequently coincided with OCA-B peaks, with their intersection increasing as a function of peak size. Among the 1000 largest OCA-B peaks, almost all coincided with OCT2 binding. By contrast, OCT2 was able to bind DNA as an isolated factor, with 35% of OCT2 binding regions lacking OCA-B interaction. Using the DNA motif discovery program MEME (27), the most strongly enriched motif within both OCT2 and OCA-B peak regions was the octamer 5'-ATGCAAAT-3' (Fig. 3D) . A slightly altered motif, 5'-ATGCATAT-3', was enriched at sites binding OCT2 in isolation and may allow for a partially overlapping palindromic motif similar to the MORE sequence identified for OCT1 binding that precludes OCA-B binding (28). No octamer-related sequence was identified within OCA-B peaks lacking OCT2 binding. The octamer motif was found with increasing frequency as a function of OCA-B peak size, being present in 80% of the largest OCA-B peaks. In contrast, in 50% of the largest OCT2 peaks, no octamer motif was present, suggesting that OCT2 may be recruited to DNA through an association with other, as yet unidentified, DNA-binding factors (Fig. 3E) . Figure 3F shows representative OCT2 and OCA-B binding profiles.
OCT2 and OCA-B regulate a broad program of B cell gene expression. To identify genes whose expression depends on OCT2 and OCA-B, we performed gene expression profiling after shRNA-mediated knockdown of these factors in 3 ABC and 2 GCB DLBCL lines. For each cell line we generated a list of genes whose expression decreased significantly following knockdown of OCT2 and/or OCA-B, and examined these lists for overlap with gene expression signatures generated from normal and malignant immune cells (Table S1 ) (29). Signatures enriched in three or more cell lines are shown in Table  S1 and include signatures of B cell transcription factor target genes (IRF4, NF-κB, STAT3, TCF3), signatures of oncogenic signaling pathways (MYD88, JAK), and signatures of B cell differentiation. We generated an "OCT2_Common_UP" signature comprised of genes changing in expression in 2 or more cell lines (Fig. S4) . The genes in this signature with OCT2 peaks in their promoter regions were defined as OCT2 direct target genes. OCT2 direct target genes that belong to functionally related signatures (Table S1 ) are summarized in Figure 4A , with those that have overlapping OCT2 and OCA-B ChIP-seq peaks highlighted in red.
Of particular interest was the regulation of genes that have established roles in germinal center biology, plasma cell differentiation or lymphomagenesis, including CD22, EBF1, ELL2, XBP1, MYC, TERT, ADA, IL10 and STAT3. For most of the enriched signatures that reflect the action of transcription factors or signaling regulators, OCT2 did not influence the expression of the regulatory factor itself but rather influenced the expression of its downstream target genes. An exception is the regulation of JAK/STAT3 signatures (Fig. S5A&B) , which appeared to be due to decreased expression of IL10 and STAT3 in the absence of OCT2, as confirmed by quantitative PCR (qPCR), ELISA and immunoblot analysis (Fig. 4B, C, D) . Direct binding of OCT2 to the STAT3 promoter was confirmed by ChIP (Fig. S5C) . We observed a significant correlation between OCT2 and STAT3 mRNA levels in both ABC and GCB DLBCL tumors profiled by RNA sequencing (RNA-seq) (30) (Fig. 4E) . A previous study suggested that OCT2 expression is itself controlled by IL10-JAK-STAT3 signaling (31). We confirmed this regulation by analysis of mRNA from HBL1 ABC DLBCL cells treated with JAK kinase inhibitors (ruxolitinib, AZD1480) or stimulated with IL10 (Fig. S5D) , suggesting the existence of positive feedback loop. Other than OCT2 itself, no single gene ( STAT3, MYC, MYB, ADA & BCL6) could reverse the toxicity of OCT2 depletion in DLBCL lines when expressed ectopically (Fig. S5E) , consistent with the concept that OCT2 regulates a network of many genes rather than a single dominant downstream target.
The genes and signatures most negatively correlated with OCT2 and OCA-B were enriched for those reflecting the action of type I interferon. Indeed, knockdown of OCT2 led to enhanced transcription from an Interferon Response Element luciferase reporter (Fig. S5F) . Furthermore, overexpression of OCT2 substantially reversed the expression of genes from the IFN-3 gene expression signature, which includes genes that are induced by interferon (Fig. S5G, H) . Thus it is conceivable that the toxicity of OCT2 depletion may be mediated in part by the induction of a type I interferon response, which is deleterious to DLBCL cells (32).
To identify genes regulated by OCT2 in normal mouse B cells, we profiled gene expression in purified splenic B cells from wild type or Pou2f2 fl/fl mice, in which Pou2f2 deletion was induced ex vivo by tamoxifen. Cells were analyzed after 48 hours of tamoxifen treatment, at which time almost complete depletion of OCT2 protein was observed by immunoblot. Analysis of genes with lower expression in the knockout B cells revealed enrichment of multiple GO ontology terms related to toll-like receptor signaling, B cell proliferation and B cell activation (Table S1 ). Individual genes of particular interest included Lmo2, Cd22, Il10, Bach2, Spib and Stat3, which were either identified as OCT2 targets in DLBCL cells or were previously suggested to be OCT2 targets. We used qRT-PCR to validate Stat3, ADA, Ell2 (each of which were also OCT2 targets in DLBCL) as OCT2 targets in sorted germinal center B cells from immunized mice. (Fig. 4F) . Taken together, these studies demonstrate that OCT2 controls a broad program of genes and pathways critical to normal B cell function in both malignant human B cells and normal mouse B cells.
Recurrent genetic aberrations targeting OCT2 in DLBCL.
Analysis of previously published array comparative genomic hybridization (aCGH) data from DLBCL identified 5 samples with amplifications encompassing the POU2F2 locus, each of which had increased OCT2 mRNA levels (Fig. 5A) (33) . In three cases, the amplicon was less than 1 megabase in size, and in the GCB DLBCL line BJAB, the amplicon only included one other gene, ZNF574, of unknown function, suggesting that these amplifications were selected to increase OCT2 expression. An additional 6 cases had amplifications of the POU2AF1 locus, encoding OCA-B, with overexpression of OCA-B mRNA (Fig. 5A) . The minimal common amplified region included only 6 other genes, none of which are expressed in B cells, suggesting that OCA-B was the focus of these genetic events. These recurrent amplifications of the genes encoding OCT2 and OCA-B suggest an oncogenic role for these factors in DLBCL.
Based on a report of OCT2 POU domain mutations in follicular lymphoma (24), we sequenced the exons encoding the POU domain in 207 cases of DLBCL. Twelve non-synonymous, heterozygous mutations were observed, with a mutational hot spot targeting threonine 223 (T223) in 7 cases, substituting either alanine or serine (Table S2) . T223 is located in the POU-specific domain and inserts into the DNA major groove, making contact with G 3 of the octamer motif (Fig. 5B) . Compared to wild type OCT2, ectopic expression of OCT2 T223A was much less effective in rescuing DLBCL cells from the toxicity of OCT2 knockdown (Fig. 5B and Fig. S6A ). To test whether the T223A mutant isoform alters OCT2 DNA binding, we designed "Biotag" constructs that express either wild type or T223A OCT2 fused to a peptide sequence that can be biotinylated by the bacterial enzyme BirA. We engineered the DLBCL cell line BJAB to express BirA, transduced the cells with the OCT2 Biotag constructs, and performed ChIP-seq using streptavidin to purify chromatin bound to these OCT2 isoforms ( Fig  S6B) . The majority of regions bound by wild type OCT2 were also bound by OCT2 T223A, indicating that T223A is not a complete loss-of-function mutant (Fig. 5D, 5G ). Roughly 10% of the T223A binding peaks (n=2975) had reduced or no binding by wild type OCT2. MEME analysis of these peaks revealed strong enrichment for an altered octamer motif 5'-ATACAAAT-3', which has an A in the position of the motif that is contacted by T223 (Fig. 5E, F, H) . To identify genes regulated by OCT2 T223A, we profiled gene expression in lymphoma lines in which we ectopically expressed either wild type or T223A OCT2 following knockdown of endogenous OCT2 expression. While OCT2 T223A-expressing cells had reduced expression of previously identified OCT2 target genes and signatures (Table S3) , the expression levels of a number of genes and signatures were increased by this mutant. This gene set was enriched for genes with OCT2 T223A binding peaks, such as FCRL2, FCRL3 and HIF1A (Table S3) . Accordingly, signatures of HIF1α-dependent target genes were enriched in HBL1 cells expressing T223A (Table S3) , and increased cell surface expression of FCRL2 and FCRL3 was confirmed by flow cytometry (Fig. S6C) .
Four of the DLBCL biopsies with OCT2 T223 were included in a previous RNASeq study (30), allowing us to search for genes that were expressed differentially in these cases versus others with wild type OCT2. Integrative analysis revealed 10 genes that were more highly expressed in OCT2 T223A+ biopsies and were also bound preferentially and upregulated by OCT2 T223A in vitro. Among these was HIF1A, and accordingly, multiple signatures of HIF1α target genes were enriched in OCT2 T223A+ cases (Table S3) . Also included was FCRL3, which was bound and regulated by OCT2 6 T223A in our cell line models. Taken together, these findings suggest that OCT2 T223 is an altered function mutant that subtly shifts the repertoire of OCT2 regulated genes.
The OCT2/OCA-B interface as a potential target for therapeutic development. Given the essentiality of both OCT2 and OCA-B in DLBCL lines, we investigated whether the interface between these two proteins might be a potential therapeutic target. The POU domain of OCT2 is highly homologous to that of OCT1, allowing us to use the crystal structure of the ternary complex between OCT1, OCA-B and the octamer motif along with mutational studies of OCT1 to predict which amino acids of OCT2 are critical for its interaction with OCA-B (5, 6). We created OCT2 and OCA-B mutant isoforms that were predicted to disrupt the association of these proteins by introducing single alanine substitutions of residues in the OCT2 POU-specific domain (L184, E185; accession NP_001234923) and the POU homeodomain (K335, I339), as well as a proline substitution of L32 of OCA-B (Fig. 6A) . Whilst the toxicity of OCT2 or OCA-B knockdown in the ABC DLBCL line OCI-Ly10 was reversed by ectopic expression of the respective wild type isoforms, the mutant OCT2 and OCA-B isoforms had little if any activity (Fig. 6B,C & Fig. S6D-G) . Thus, the residues that facilitate the interaction of OCT2 and OCA-B are essential for the survival of DLBCL cells.
Discussion
Our genetic and functional analyses have clarified the role of OCT2 in normal and malignant B cells. Previous studies of Rag2-deficient mice reconstituted with OCT2 knockout bone marrow have yielded conflicting evidence regarding the role of OCT2 in the germinal center reaction (14, 15) . By conditional deletion of Pou2f2, we observed normal formation of germinal centers in the absence of OCT2, yet the cell cycle progression of the B cells in these germinal centers was impaired. While the development of memory B cells proceeded normally following immunization of OCT2-deficient mice, these mice were strikingly unable to form antibody-secreting plasma cells. Hence, our genetic analysis revealed that OCT2 influences the dynamic behavior germinal center B cells in vivo by promoting their proliferation and plasmacytic differentiation.
In contrast to the rather selective germinal center defects resulting from OCT2 deficiency, we observed that all human DLBCL lines tested are strongly addicted to the expression of OCT2. DLBCL tumors arises from normal B cells that have traversed the germinal center, and either retain the germinal center phenotype, in the case of the GCB subtype, or undergo partial plasmacytic differentiation, in the case of the ABC subtype. The fact that OCT2-deficient germinal center B cells have a defect in proliferation may contribute to the toxicity of OCT2 knockdown in DLBCL lines. However, depletion of OCT2 in DLBCL not only blocks proliferation, but also induces cell death, suggesting that OCT2 functions in a somewhat different or augmented fashion in malignant versus normal B cells. A role for OCA-B in DLBCL was previously revealed by the discovery of a DLBCL-specific super-enhancer in the POU2AF1 locus (23), but this study did not address whether OCA-B mediates its effects in DLBCL through OCT1 or OCT2. We cannot exclude a contribution from OCT1, however, our data suggest that OCT2 is the key factor cooperating with OCA-B, a view that is supported by our genetic analysis of DLBCL tumors, which revealed recurrent amplification of POU2F2 locus. Likewise, we observed recurrent amplification of the POU2AF1 locus in DLBCL tumors, but not the POU2F1 locus, which encodes OCT1. However, amplification of POU2F2 and POU2AF1 were detected in only ~3% (5/172) of DLBCL tumors tested, which by itself might have led to the conclusion that OCT2 and OCA-B contribute only infrequently to DLBCL pathogenesis. Given the universal addiction of DLBCL lines to OCT2 and OCA-B, our study highlights the power of functional genomic methodologies to uncover essential cancer mechanisms.
By combining ChIP-seq with gene expression profiling, we identified multiple OCT2 target genes that play important roles in B cell function and differentiation, including ELL2, XBP1, MYC, TERT, ADA, IL10 and STAT3. Gene expression signature analysis revealed that many of the OCT2 target genes are involved in key regulatory pathways in DLBCL (MYD88, NF-κB, STAT3 and IRF4). Although OCT2 did not directly regulate IRF4 or PRDM1, the direct regulation of STAT3 and its activation by autocrine production of IL-10 were particularly intriguing given the known role of STAT3 in the transactivation of PRDM1 and the initiation of plasma cell differentiation. STAT3 appears to play a particularly important role in the differentiation of germinal center B cells to plasma cells (34), an effect that may depend upon synergism with CD40 signaling (35). There are similarities between the phenotypes of OCT2 conditional knockout mice and IL-21 receptor knockout mice, in which germinal centers and memory B cells are formed but germinal center proliferation and plasma cell differentiation are reduced (36), which is intriguing given that IL-21 receptor signaling activates STAT3. The OCT2 target ELL2 is required for the alternative splicing needed to produce soluble immunoglobulin and regulates the unfolded protein response during plasma cell differentiation, together with XBP1, also an OCT2 target. Ell2 knockouts show decreased plasma cell numbers as well as also reduced expression of OCA-B suggesting a feed forward loop during plasma cell differentiation (37). The OCT2 target gene ADA encodes adenosine deaminase, which prevents apoptosis during B cell activation and is required for the formation of germinal centers (38). Thus, the identified OCT2 transcriptional program is consistent with the growth and survival of normal and malignant germinal center B cells and also with the control of post-germinal center plasma cell differentiation by OCT2.
The recurrent POU2F2 T223A mutation targets a residue in the POU-specific domain that directly contacts the octamer motif within the DNA major groove. A previous analysis posited that this mutation was loss-of-function (24), but this conflicts with other evidence that OCT2 performs an oncogenic function in DLBCL and with the fact that DLBCL tumors do not acquire nonsense or frame shift mutations in POU2F2, nor do they delete this gene frequently. Instead, our ChIP-Seq and gene expression data suggest that the OCT2 T223A is a neomorphic mutation that is associated with some reduction in transcriptional programs regulated by wild type OCT2 (Table S3) , but also a gain in expression of non-canonical target genes that have an altered octamer motif in which the base contacted by T223 is changed from guanine to adenine. In DLBCL tumors, the T223A mutation is invariably heterozygous, suggesting a role for the remaining wild type OCT2 allele. This observation may explain why cells engineered to only express OCT2 T223A were not as fit as those with wild type OCT2. Alternatively, DLBCL tumors with OCT2 T223A may acquire additional genetic or epigenetic changes that permit them to tolerate its altered regulatory repertoire. In this regard, an intriguing hypothesis is that the OCT2 T223A isoform may promote lymphomagenesis by blocking plasmacytic differentiation, which OCT2 normally promotes. Indeed, genetic events that block full plasmacytic differentiation are recurrent in ABC DLBCL, including multiple lesions that inactivate Blimp1 (reviewed in ref. (39)). Hence, DLBCL tumors may acquire T223A and lose one wild type OCT2 allele in order to partially block plasmacytic differentiation. In addition, one of the non-canonical targets of OCT2 T223A is FCRL3, which encodes a transmembrane protein with both ITAM and ITIM domains that enhances TLR9-mediated B cell proliferation and survival while at the same time inhibiting plasma cell differentiation (40). Future analysis of T223A knock-in mice would be helpful in testing the hypothesis that OCT2 T223A blocks post-germinal center plasmacytic differentiation.
The present study identifies OCT2 as an attractive therapeutic target in DLBCL. Knockdown of OCT2 was toxic to models of both ABC and GCB DLBCL, suggesting that agents targeting OCT2 would transcend the many regulatory differences between these subtypes (39). Recent clinical trials have focused on oncogenic pathways in ABC DLBCL (41) but methods to target GCB DLBCL are also needed. The B cell-restricted expression of OCT2 and OCA-B suggest that inhibition of these proteins in human patients would not be associated with generalized toxicity. Consistent with this, the induced deletion of OCT2 in adult mice was associated with no outward signs of ill health. Finally, our work suggests that agents targeting the OCT2/OCA-B interface might be one possible strategy. Alternatively, new methods to target proteins for destruction using small molecules (42, 43) might be aimed at OCT2 for the therapy of DLBCL.
Materials and Methods
Pou2f2 targeted JM8A3.N1 embryonic stem cells were purchased from the EUCOMM Consortium; clone ID HEPD0690_4_H11, IKMC Project 82506, allele name Pou2f2_tm1a(EUCOMM) Hmgu, MGI allele ID MGI:101897. All animal experiments were carried out in accordance with the National Cancer Institute Animal Care and Use Committee guidelines and approval. A detailed description of all methods is available in the SI Materials and Methods. HT (4) ULA (3) WSDLBCL2 (4) DOHH2 (3) OCI-Ly19 OCI-Ly7 SUDHL4 ( Cre expression was induced by intraperitoneal injection of tamoxifen (Sigma) given as five doses with a minimum seven day interval before immunization or analysis as previously described(44).
Southern blotting
Genomic DNA was digested overnight with the indicated restriction enzymes, run on an agarose gel and transferred to Hybond-XL membrane as per manufacturers protocol. Neo probes and flanking probes were labelled using the Rediprime labelling kit and hybrisized using Rapid-Hyb buffer (both from GE) and used as per the manufacturer's protocols. Probes were cloned using the flowing primers: Neo-F; 5'-AACAAGATGGATTGCACGC-3', Neo-R;5'-CGGGTAGCCAACGCTATGTC-3', Flanking-F 5'-TTGGAGAGCCTTTGGAAGAA-3', Flanking-R 5'-GCCTTCCTTATCACCCAACA-3'
Immunizations
For primary immunisation mice (8-12 weeks old) received intraperitoneal injection of 100ug of NP(19)-KLH (Biosearch Technologies) adsorbed to Alum (Thermo Scientific). For secondary immunisation soluble NP(19)-KLH alone was used. Blood was collected by tail bleed or terminal cardiac puncture at the indicated time points. For germinal center induction mice were immunised with 100ul of 10% sheep red blood cells (Colorado Serum Company).
Measurement of NP-specific immunoglobulin and antibody secreting cells
Maxisorb (Nunc) ELISA plates were coated with 1µg/ml NP(27)BSA or NP(4)BSA in carbonate buffer before blocking in 1% BSA. Dilutions of serum were added. Captured immunoglobulin was detected using anti-IgM or IgG1 conjugated to HRP (Southern Biotechnology Associates). SigmaFast OPD substrate reagent (Sigma) was added and the reaction quantified using a Spectromax 250 96-well plate reader. Values in the linear range were used to calculate relative titre using the endpoint dilution method(45). For ELISpot Multiscreen HA mixed cellulose ester plates (Millipore) were coated with NP-BSA in PBS before blocking in 1% BSA and incubation overnight with a known concentration of cells. Plates were then washed with PBS/Tween and incubated with anti-IgM or IgG1 conjugated to HRP (Southern Biotechnology Associates). Spots were then visualized using the AEC staining kit (Sigma) and counted on a CTL-Immunospot Analyzer.
Mouse cell FACS and sorting
Flow cytometry analysis was performed on an LSRII (BD). FlowJo software (TreeStar) was used for data analysis. Cell suspensions of murine splenocytes were prepared in PBS with 2% FCS. Red cells were removed using Red Cell Lysis Buffer (Biolegend) then pre-incubated with purified anti-CD16/CD32 FC blocking antibody (eBioscience) prior to immunostaining with the following antibodies or markers: B220, CXCR4, CD83, CD86 (eBiosciences), CD95, CD11b, Gr1, IgD, CD138 (BD), IgG1, CD38 (Biolegend), PNA (Sigma), NP-BSABiotin (Biosearch). The EdU staining kit (Life Technologies) was used as per the manufacturer's protocol. Mice received one intraperitoneal injection of EDU 5 hours prior to harvesting splenocytes for FACS analysis of germinal center B cells. FACS sorting was performed on a FACSAria cell sorter. Prior to sorting of mouse germinal center B cells, splenocytes were pre-enriched my magnetic selection as previously described(46). Intracellular staining of lymphoma cell lines was performed after fixation with Cytofix/Cytoperm using Caspase3 and cleaved PARP antibodies from BD biosciences. Cell cycle analysis was performed after staining with DAPI (Sigma).
In vitro stimulation murine B cells B lymphocytes were purified from spleens of non-deleted mice by magnetic bead technology (B cell isolation kit, mouse, Miltenyi Biotech). Cells were stimulated in vitro with 5ug/ml anti-IgM (Jackson), 10ng/m lIL4 (Promega) in the presence of 5-OH-tamoxifen (Sigma). At 48 hours OCT2 was efficiently depleted and 50ng/ml IL21 (Promega) was added. Cells were harvested 12 hours later.
RNA extraction and qPCR
Cells were lysed in Trizol and RNA purified using RNeasy columns (Qiagen). CDNA was made using Superscript III (Life technologies). Taqman assays were run an ABI7500 instrument (Applied Biosystems) using the following assays hB2M (Hs00984230_m1), hIL10 (Hs00961622_m1), mPou2f2 (Mm01149405_m1), mStat3 (Mm01219775_M1), mAda (Mm00545720_m1), mEll2 (Mm00507237_m1).
Lymphoma cell line culture and retroviral production OCI cell lines were cultured in Iscove's medium with 20% fresh human plasma. All other cell lines were cultured in RPMI, penicillin/streptomycin and 10% fetal bovine serum. Cells were maintained in a humidified, 5% CO2 incubator at 37°C. All cell lines were engineered to express an ecotropic retroviral receptor and the bacterial tetracycline repressor as previously described(47). Production of retroviruses was performed by co-transduction of 293T cells, with Transit293 (Mirus) with plasmids containing gag & pol genes, the ecotropic envelope protein, and the retroviral construct.
Plasmids
OCT2 was cloned from cDNA from BJAB and OCA-B cDNA was purchased from Origene. Both were cloned into the vectors pCMV-TOP and pFlagBiopCMV-TOP(30). Site directed mutations were introduced using the QuikChange Lightning kit from Agilent. shRNAs targeting OCT2 or OCA-B were designed and cloned as double stranded oligonucleotides into a retroviral vector (pRSMX_PuroGFP) for doxycycline-inducible shRNA expression, as previously described(47). RNAi sequences used are as follows: OCT2 shRNA#1_1196 5'-GCACAACAGTTACTACCTTAT-3', OCT2 shRNA#2_3410 5'-GGATGCTTCTTTCTCTTCACA-3', OCA-B shRNA_3017 5'-CAGCCAGAAGTACCATTAGG-3'. Because OCT2 shRNA#1 targeted the coding region of OCT2 silent mutations were introduced into the recognition site to allow the shRNA to be rescued by OCT2 constructs.
shRNA experiments
The pRSMX-PG vector coexpressing GFP and shRNA was introduced into cells and where required selection was carried out with puromycin. Expression of shRNA was induced by addition of doxycycline (50 ng/mL). For toxicity screen, the fraction of GFP+, shRNAexpressing cells was quantified by flow cytometry using a BD FACS Calibur at the indicated time points and normalized to the day 0 fraction of GFP+ cells.
Western blotting
Cell pellets were lysed in RIPA buffer with a protease inhibitor cocktail (Roche), separated on 4-12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Antibodies used were OCT2 (SC-233), OCA-B (SC-955) and Actin-HRP (Santa Cruz) and STAT3 (CST).
IL10 ELISA and IFN reporter assay IL-10 was quantified using the IL-10 Quantikine colorimetric sandwich enzyme-linked immunosorbent assay kit (R&D Systems) according to the manufacturer's instructions. IFN reporter experiments were conducted using a previously described reporter cell line(32)
Chromatin immunoprecipitation and ChIP-Seq
ChIP and ChIP-Seq was performed as previously described (48) BioChIP N-terminally tagged OCT2 in the vector pRCMV/TOP_Flag-Bio or empty vector was used to transduce cells engineered to express the BirA enzyme. Selection was carried out using puromycin.
BioChIP, sequencing and differential peak analysis was performed as described(30).
Gene expression profiling by microarray
Total RNA was extracted with TRIzol (Invitrogen) and subsequently cleaned up with RNeasy mini columns (Qiagen). Gene expression profiling was performed using two-color human Agilent 4×44K or mouse 8x60K gene expression arrays, as described by the manufacturer, comparing signal from control cells (Cy3) and experimentally manipulated cells (Cy5). Array elements were filtered for those meeting confidence thresholds for spot size, architecture, and level above local background. These criteria are a feature of the Agilent gene expression software package. Gene set enrichment was performed as previously described (30). GO term analysis was performed using the PANTHER classification system Two shRNA (OCT2#1 and OCT2#2) were transduced, selected and induced in five DLBCL cell lines. RNA was harvested for each at 24 and 48 hours post induction to give 4 data points per cell line. Significantly changing genes were those with log2 fold change >0.4 up or down in three or more data points. Genes with decreased expression in two or more cell lines were used to generate the OCT2_Common_UP signature. Also shown is the OCT2_Common_UP signature genes in a replicate HBL1 and Ly10 experiment and an OCA-B shRNA knockdown experiment. (Table 4A) or genes with enhanced or reduced expression (measured by RNA-seq) in human DLBCL biopsies from tumors with T223A mutated OCT2 compared to cases with wild type OCT2 (Table 4B ). Enrichment analysis of B cell signatures (including OCT2 signatures) amongst genes with altered expression in cell lines in which OCT2 was knocked down and rescued by T223A vs WT OCT2 (Table 4C) . HBL1 (4) OCI-Ly10 (4) OCI-Ly3 (3) SUDHL2 (5) TMD8 (4) U2932 ( (4) DOHH2 (2) HT (3) OCI_Ly19 (3) OCI-Ly7 (3) SUDHL4 (6) ULA (4) WSDLBCL2 (4) RASSF6  AEN  MAP3K6  SIRT3  MMP11  LRRC16B  PRR7  HOXA5  POU2F2  POLR3D  FUZ  RCC1  EIF2S2  ITPR3  COMTD1  C16orf59  HMBS  RPS2  HSPA4L  PLEKHA1  ACTG2  RCC2  ARG2  MCM7  ZDHHC21  C12orf29  FAM120C  ASRGL1  NAPEPLD  CSRP2  B4GALT2  SYDE2  RGS16  TNFRSF21  MYB  MYBBP1A  TMEM177  PHC2  GATM  NAT8L  GRK5  STEAP1  COCH  SNHG7  RPL27A  GDF11  AEBP1  FRMD4A  CD22  BTBD16  FCRL5  OVOL2  TM7SF2  P2RY8  FAAH2  FLNB  FA2H  PODXL  GNB3  LEPREL2  CTDSP2  XBP1  LSS  ZDHHC23  TSPAN4  HSP90B1  CKAP4  CCL17  NPAS1  FCRL2  FCRL3  GGA2  CABLES1  PARD6A  EBF1  ELL2  RIMS3  KCNA3  TIMP2  IL12A  GEN1  MAN2A2  KHK  KBTBD11  HIP1R  ALOX5  ASMT  MMD  SLC6A16  SOBP  BIK  FCRL1  GSTP1  GUCY2C  TNFAIP2  IRAK3  SALL2  LRRC56  PDE4B  SH2D5  FJX1  VSNL1  VASH2  MOCOS  HSD17B6  LRRC8B  SEPHS1  DENND1A  C9orf24  SLC44A1  REEP2  DLL3  STAT3  CD1C  F12  TMEM18  SNAI3  PRDM2  KHDC1  TBC1D27  XRCC2  CALM1  MLXIP  IGL@  PCYOX1  THAP2  LRP5  AVIL  DERL3  MCM9  NUPL1  ELOVL6  MMAB  GADD45A  SCD  MVK  REPIN1  ZNF292  C1orf213  PSIP1  F11R  ACSL3  SPRED1  NHEDC2  KIAA1715  TMED2  CRTC3  RGPD1  TMEM135  IGHG1  PFKFB3  GHRL  TMEM151B  PAPOLG  TNS3  ACSS1  RASL10B  LGALS7  MGST3  ROPN1L  ACTL8  IRS2  FAM71E1  ST7  SLC4A7  SKP2  IL10  IDH3A  MYC  SRRM1  PFKFB4  ALDOC  HAGHL  SLC25A23  ANKZF1  ATP1A1  ENO1  CLN6  CD320  NME4  PODXL2  NT5DC2  PARVB  GAMT  MFSD10  CD81  NUP210  PAQR4  CHID1  MFSD3  DPAGT1  RAB11FIP4  C14orf1  PLTP  GYPC  FSTL3  METRN   CANT1  ECE1  PRKCSH  IGSF8  GPR183  PLD3  DHRS9  MIAT  APH1A  NINJ1  SLC38A5  B4GALT3  TNFRSF12A  CMTM8  FMNL2  BCAR1  DIXDC1  NTN1  GYS1  WNK2  KCNJ11  SDK1  CHST6  CENPL  SLC5A6  ATP1A4  REN  SNORD22  ARHGEF4  RNF39  CD177  SCRT1  FLJ35946  CACNA1B  WBSCR17  HOXA6  SYCN  LRRC4B  C2orf51  GRIN3B  LOXL4  TUB  COL9A1  PKLR  LTK  CTXN1  SCT  CSF3R  TNXB  ABCC6  TTBK2  NOTCH3  KANK3  PCDH1  LSAMP  ADA  NLRP7  CCDC151  MYO10  FLJ26850  CTSB  ZNF765  HAB1  KIR3DS1  IGFALS  INTS1  KCNQ4  LRRC61  MAPK15  CNKSR2  HIST2H2BE  HIST1H2AD  CITED1  HSPA12B  HPN  TNNT2  ALOX15  MYBPH  ERGIC1  RNASET2  AGRP  CHAD  HDLBP  VPS13B  ADRA2C  VPS53  NRN1  SSTR2  SCML4  SOCS1  TMEM100  SYNGR1  RASGRP1  DCN  SPIC  ATP12A  NMU  TAS1R3  EXOC3L4  TERT  C6orf48  SOCS2  CR2  ACSL1  SIGLEC10  PHLDA1  BBC3  CFLAR  ASB13  CLCN2  SNRPB  ZNF598  VAMP2  GCH1  PAPSS1  GFOD1  CCDC28B  GSTA4  CHN2  VDAC1  KIAA1147  TTC28  SH3BP5  NOL10  DUT  NUFIP1  TRIM2  TTC7B  IPO7  RGS12  GRHL2  GPR45  PDGFD  SERPINA9  TJP2  ABCA3  BANK1  PLEKHG1  CNR2  FCRL4  CPNE5  RIMS1  HEPACAM2  GEM  TEC  GNPDA1  PCSK5  SLCO3A1  RAB9A  C11orf82  ZFP106  GNAZ  EFR3B  CCRL1  PHF15  PARD3  GCET2  HBD  C22orf23  TRHR  LIF  HS1BP3  MAN1B1  ST3GAL4  NPW  TBC1D22B  TRPV6  SHH  NPC1  SEMA4D  ACP5  HSPA6  ICOSLG  C10orf10  DACT3  RYR1  GPR146  SOX2  ROR2  GPR18  FERMT3  KCNN4  LRRC32  TINAGL1  KLF1  PCDHB9  FLJ31356  PTRF  ACTBL2  RAC3  ANXA4  CASP10  PARP14  RTDR1  CD69  JUN (Log2) BANK1  FLI1  CD53  GLRX  BCL3  DHRS9  MCL1  PDIA3  SCARB1  FUT8  BIRC3  DENND3  MAP2K1  CD44  SOCS3  ZMIZ1  MIR155HG  MNDA  RASGRP1  ACTG2  CAMK2D  JUN  PNP  GPR183  SOX4  STAT3  EIF2S2  REEP5  PDIA4  ARPC2  EIF5  PPP6C  STK38L  MYB  LDHA  SLC25A5  CSNK2A1  CHEK1  ENO1  PLOD1  SLC7A5  PGAM1  CDC123  OTUB1  AURKA  EIF4E  JAK1  LMO2  VASP  SCYL1  ITGB1  BIRC2  POU2AF1  NDUFA8  SOCS1  GNB1  TCF12  HIF1A  VBP1  NAMPT  PPP2R1A  CSK  GNB2  TUBG1  CTH  MTHFD2  FAS  IMPDH1  FTSJ1  HN1  UBE2V1  TOR1A  GNAI3  PRDX4  PRR11  CTSL1  PTPN1  IL21R  CD40  ID2  DOK1  HCK  LSM6  NFKBIA  BCL2A1  PLEK  DUSP5  SGK1   IFIT1  OASL  IFI44  MX1  DDX58  IFI27  OAS3  SAMD9  IFIT3  DDX60  USP18  ISG15  STAT1  OAS2  LAMP3  LAP3  HERC6  IFIH1  OAS1  IFI35  PARP12  TRIM5  BCL2L13  PDK4  HSPA1A  PRPF4B  TNFSF10  TRIM14  HPGD  PGRMC2  HERC5  GRB14  TLR3  C14orf2  HSPA6  ID3 LHX2  POU3F1  CASP10  JAK2  TRANK1  DDX60L  DDX60  OAS2  CMPK2  EPSTI1  ISG15  HERC6  STAT1  IFIT1  IFIT3  MX1  XAF1  IFIT5  DHX58  IRF9  ADAR  IFIT2  IFI6  OASL  OAS3  SAMD9L  TRIM22  PHF11  IFIH1  DUSP5  GBP1  PLSCR1  IFI16  CCDC75  IFI44L  IFI44  EIF2AK2  LAP3  NMI  PSME2  CASP7  ZBP1  ENDOD1  ZNFX1  LAMP3  LAG3  DDX58  PARP12  NCOA7  PARP14  TRIM25  OAS1  PML  APOBEC3G  IFI35  SAMD9  RGS1  FBXO6  IFITM1  SP110  TNK2  C19orf66  TRIM21  AGRN  DRAP1  UBE2L6  WARS  VAMP5  RNF213  RAB8A  GNA13  ZEB1  CCL5  C9orf46  SLC6A4  GBP2  DYNLT1  DNAJA1  MELK  PNPT1  RTP4  CASP1  RIPK1  FCHSD2  RABGAP1L  MX2  BST2  CHMP5  MAN1A2  AKAP12  PNP  HLA-DOA  APOL1  PARP9  DTX3L  RSAD2  PSMB9  PSMB8  CCRL2  NT5C3  TAP1  FAS  AXL  C22orf28  GBP4  IRF7  LY6E  TRIM5  PRKD2  MOV10  MYD88  NAPA  OGFR  FTSJD2  MICB  DBNL  MAX  IL15  UBA7  TYMP  LGALS9  TNFSF10  IFITM2  IFITM3  IRF1  TREX1  MT1X  MT1G  MT1B  PSMB10  PROCR  SPPL2A  STAT2  ACTA2  RIN2  KLRC4-KLRK1  LGALS3BP  PRIC285 WT  WT  SPECS2601 ABC  WT  WT  SPECS2612 ABC  WT  WT  SPECS2614 ABC  WT  WT  SPECS2635 ABC  WT  WT  SPECS2641 ABC  WT  WT  SPECS2648 ABC  WT  WT  SPECS3633 ABC  WT  WT  SPECS41  ABC  WT  WT  SPECS41  ABC  WT  WT  SPECS47  ABC  WT  WT  SPECS47  ABC  WT  WT  SPECS48  ABC  WT  WT  SPECS48  ABC  WT  WT  SPECS97 GCB  WT  WT  SPECS107 GCB  WT  WT  SPECS1091 GCB  WT  WT  SPECS1097 GCB  WT  WT  SPECS111 GCB  WT  WT  SPECS1169 GCB  WT  WT  SPECS1172 GCB  WT  WT  SPECS1173 GCB  WT  WT  SPECS118 GCB  WT  WT  SPECS1181 GCB  WT  WT  SPECS1184 GCB  WT  WT  SPECS1187 GCB  WT  WT  SPECS1189 GCB  WT  WT  SPECS119 GCB  WT  WT  SPECS1190 GCB  WT  WT  SPECS1190 GCB  WT  WT  SPECS1195 GCB  WT  WT  SPECS1197 GCB  WT  WT  SPECS1215 GCB  c.667A>G  p.T223A  SPECS1222 GCB  WT  WT  SPECS1228 GCB  WT  WT  SPECS1231 GCB  WT  WT  SPECS1252 GCB  WT  WT  SPECS1271 GCB  WT  WT  SPECS1277 GCB  WT  WT  SPECS1284 GCB  WT  WT  SPECS1290 GCB  WT  WT  SPECS1291 GCB  WT  WT  SPECS1293 GCB  WT  WT  SPECS1294 GCB  WT  WT  SPECS1331 GCB  WT  WT  SPECS1334 GCB  WT  WT  SPECS1336 GCB  WT  WT  SPECS1451 GCB  WT  WT  SPECS1453 GCB  WT  WT  SPECS1454 GCB  WT  WT  SPECS1612 GCB  WT  WT  SPECS1613 GCB  WT  WT  SPECS1614 GCB  WT  WT  SPECS1617 GCB  WT  WT  SPECS1620 GCB  WT  WT  SPECS1626 GCB  WT  WT  SPECS1647 GCB  WT  WT  SPECS1707 GCB  WT  WT  SPECS1782 GCB  WT  WT  SPECS1782 GCB  WT  WT  SPECS1861 GCB  WT  WT  SPECS1916 GCB  WT  WT  SPECS1920 GCB  c.667A>G  p.T223A  SPECS2006 GCB  WT  WT  SPECS2067 GCB  WT  WT  SPECS2070 GCB  WT  WT  SPECS2070 GCB WT WT 
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